Company
Agenus
Agenus is a biopharmaceutical company developing immunotherapies designed to activate the immune system to recognize and eliminate cancer. The company's lead program, botensilimab plus balstilimab (BOT+BAL), is in clinical trials for colorectal cancer, merkel cell carcinoma, and sarcoma. Agenus aims to reduce patient reliance on chemotherapy, radiation, and surgery.
Agenus is a publicly traded company operating in the biotechnology sector, based in the United States. It trades on the Nasdaq under the ticker AGEN. Leadership tracked by CEOInsider includes Garo H. Armen (CEO).
Leadership
Current
